SUMMER CLAY: Open Payments
NPI 1740680354 · BATTLE CREEK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,776 in 103 payments from 18 companies in 2025. Trend: 2023 $2,053 · 2024 $2,040 · 2025 $1,776
Food & beverage: $1,776
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $330 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $259 |
| ABBVIE INC. | 22 | $239 |
| Vanda Pharmaceuticals Inc. | 12 | $236 |
| AstraZeneca Pharmaceuticals LP | 7 | $183 |
| GlaxoSmithKline, LLC. | 5 | $91 |
| Axsome Therapeutics, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Lundbeck LLC | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
Products named: CAPLYTA, FANAPT, REXULTI, VRAYLAR, Ozempic, Wegovy, TRELEGY ELLIPTA, Auvelity.
Industry payments across MI — which companies pay providers there.
